secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harmony Biosciences Holdings, Inc. (HRMY)
CIK:        0001802665
Form:       8-K
Filed at:   2026-08-04T12:05:12+00:00
Accession:  0001104659-26-090086
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harmony Biosciences Q2 revenue $261.3M (+30% YoY); EPS $1.28; reiterates FY guidance $1.0-1.04B
--------------------------------------------------------------------------------

- Q2 net revenue $261.3M, up 30% YoY; average patients 8,950 (+450).
- Net income $75.4M ($1.28 diluted EPS) vs $39.8M ($0.68) in Q2 2025.
- Reiterates 2026 WAKIX net revenue guidance of $1.0B-$1.04B.
- BP-205 Phase 1 SAD data favorable; Phase 1b in sleep-deprived volunteers starts Q3; Phase 2 mid-2027.
- Cash and investments $962.5M as of June 30, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802665/000110465926090086/0001104659-26-090086-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802665/000110465926090086/hrmy-20260804x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-090086

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer